Evidence map›Paper›PMID 25768286›Full record

ArticlePloS one2015

SPARCoC: a new framework for molecular pattern discovery and cancer gene identification.

Shiqian Ma, Daniel Johnson, Cody Ashby, Donghai Xiong, Carole L Cramer, Jason H Moore, Shuzhong Zhang, Xiuzhen Huang

Abstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Shiqian MaDepartment of Systems Engineering and Engineering Management, The Chinese University of Hong Kong, Shatin, N.T. Hong Kong.
Daniel JohnsonMolecular Biosciences Program, Arkansas State University, Jonesboro, Arkansas 72467, United States of America.
Cody AshbyMolecular Biosciences Program, Arkansas State University, Jonesboro, Arkansas 72467, United States of America.
Donghai XiongDepartment of Pharmacology and Toxicology and the Cancer Center, Medical College of Wisconsin, Milwaukee, Wisconsin 53226, United States of America.
Carole L CramerArkansas Bioscience Institute and Department of Biological Sciences, Arkansas State University, Jonesboro, Arkansas 72467, United States of America.
Jason H MooreThe Geisel School of Medicine, Dartmouth College, Lebanon, New Hampshire 03756, United States of America.
Shuzhong ZhangDepartment of Industrial and Systems Engineering, University of Minnesota, Minneapolis, Minnesota 55455, United States of America.
Xiuzhen HuangDepartment of Computer Science, Arkansas State University, Jonesboro, Arkansas 72467, United States of America.

Funding

Translational Engineering in Cancer (TEC)P30CA023108 · NCI · DARTMOUTH COLLEGE · PI Steven D Leach · 1985 to 2026
$91.3M
Understanding Hesitant AdoptersP20GM103429 · NIGMS · UNIV OF ARKANSAS FOR MED SCIS · PI Lawrence E Cornett, JERRY WARE · 2012 to 2026
$60.9M
VIRULENCE MECHANISMS IN ESCHERICHIA COLIP20RR016460 · NCRR · UNIV OF ARKANSAS FOR MED SCIS · PI HENSLEY, LORI · 2001 to 2011
$33.1M
Bioinformatics Strategies for Genome-Wide Association StudiesR01LM010098 · NLM · UNIVERSITY OF PENNSYLVANIA · PI MOORE, JASON H., WILLIAMS, SCOTT MATTHEW · 2009 to 2023
$5.1M
Machine Learning Prediction of Cancer SusceptibilityR01LM009012 · NLM · UNIVERSITY OF PENNSYLVANIA · PI MOORE, JASON H. · 2006 to 2014
$3.3M
NCI NIH HHS P30 CA023108NCRR NIH HHS P20 RR016460NCRR NIH HHS P20RR016460NIGMS NIH HHS P20 GM103429NIGMS NIH HHS P20GM103429NLM NIH HHS LM009012NLM NIH HHS LM010098NLM NIH HHS R01 LM009012NLM NIH HHS R01 LM010098
6 · The paper itself

Abstract

It is challenging to cluster cancer patients of a certain histopathological type into molecular subtypes of clinical importance and identify gene signatures directly relevant to the subtypes. Current clustering approaches have inherent limitations, which prevent them from gauging the subtle heterogeneity of the molecular subtypes. In this paper we present a new framework: SPARCoC (Sparse-CoClust), which is based on a novel Common-background and Sparse-foreground Decomposition (CSD) model and the Maximum Block Improvement (MBI) co-clustering technique. SPARCoC has clear advantages compared with widely-used alternative approaches: hierarchical clustering (Hclust) and nonnegative matrix factorization (NMF). We apply SPARCoC to the study of lung adenocarcinoma (ADCA), an extremely heterogeneous histological type, and a significant challenge for molecular subtyping. For testing and verification, we use high quality gene expression profiling data of lung ADCA patients, and identify prognostic gene signatures which could cluster patients into subgroups that are significantly different in their overall survival (with p-values < 0.05). Our results are only based on gene expression profiling data analysis, without incorporating any other feature selection or clinical information; we are able to replicate our findings with completely independent datasets. SPARCoC is broadly applicable to large-scale genomic data to empower pattern discovery and cancer gene identification.

Indexed as

Cluster AnalysisGenes, NeoplasmAdenocarcinomaAdenocarcinoma of LungAlgorithmsBiomarkers, TumorDatabases, GeneticDatasets as TopicGene Expression ProfilingGenetic TestingHumansLung NeoplasmsPattern Recognition, AutomatedBiomarkers, Tumor

Identifiers

PMID25768286
PMCPMC4359112

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.